GVP Module VIII: Imposed and Non-Imposed PASS

Introduction

The distinction between imposed and non-imposed post-authorisation safety studies is fundamental because the reason a study exists determines the regulatory framework within which it is conducted.

A PASS may be undertaken voluntarily by a marketing authorisation holder, included in an agreed risk management plan, or required by a competent authority. These situations can involve similar scientific methods, but they do not create identical regulatory obligations.

The distinction should therefore be established before the study is designed. If the regulatory basis is misunderstood, the organisation may apply the wrong submission route, misunderstand the significance of a protocol change, or close a study without addressing a continuing regulatory obligation.

1. Start With the Regulatory Basis

The first question is not simply "Is this a PASS?" It is "Why is this PASS being conducted?"

Under GVP Module VIII, non-interventional PASS conducted by a marketing authorisation holder can be undertaken voluntarily or pursuant to an obligation imposed by an EU competent authority. Imposed non-interventional PASS include studies imposed as a marketing-authorisation condition and studies imposed as a specific obligation in certain exceptional or conditional authorisation circumstances. PASS may also be required in an RMP to investigate a safety concern or evaluate the effectiveness of risk-minimisation activities. citeturn0search21

These categories overlap scientifically but differ in their legal and procedural consequences.

2. A Useful Conceptual Model

The relationship can be represented as:

Safety question
      ↓
Why is evidence being generated?
      ↓
Regulatory basis of the study
      ↓
Applicable legal / procedural framework
      ↓
Governance and submission requirements
      ↓
Study conduct and reporting
      ↓
Regulatory or pharmacovigilance consequence

This is why classification should occur at the beginning of the study lifecycle rather than being added later as an administrative field.

3. What Makes a PASS Imposed?

An imposed PASS is a study required by an EU competent authority under the applicable legal framework.

For non-interventional imposed PASS, GVP Module VIII identifies categories including studies imposed as conditions of a marketing authorisation and studies imposed as specific obligations. These studies are subject to the provisions applicable to imposed non-interventional PASS, including Articles 107n–q of Directive 2001/83/EC where applicable. citeturn0search21turn0search0

The key feature is therefore not who performs the study or whether the study is epidemiological. It is the regulatory source of the obligation.

4. What Is a Non-Imposed PASS?

A non-imposed PASS is not subject to an obligation imposed by an EU competent authority under the imposed-PASS framework.

It may nevertheless be highly important to the pharmacovigilance system. A PASS may be conducted voluntarily because the MAH considers that additional evidence is needed to understand a safety concern, characterise risk or evaluate a risk-minimisation measure.

A study may also be included in an agreed RMP. Its inclusion in the RMP makes the study part of the product's risk-management framework, but that fact should not automatically be treated as equivalent to an imposed PASS obligation.

RMP inclusion and regulatory imposition are different concepts.

5. Imposition and RMP Inclusion Are Not Synonyms

The organisation must identify the actual regulatory basis recorded for the study rather than infer it from where the study appears in the RMP.

A controlled study inventory should record, where relevant:

• study objective;
• PASS classification;
• regulatory basis;
• RMP relationship;
• authority or procedure creating an obligation, if applicable;
• relevant milestones; and
• applicable submission route.

This avoids treating every RMP PASS as though it were an imposed PASS.

6. Why the Classification Matters

For an imposed non-interventional PASS, the EU framework contains specific requirements for protocol submission, substantial amendments, final study reports and regulatory assessment. EMA states that imposed non-interventional PASS are assessed by PRAC, except for studies conducted in only one Member State under the applicable Article 22a route, where the relevant national competent authority performs the assessment. citeturn0search0

For voluntary PASS, the same regulatory procedures do not automatically apply as legal obligations. EMA nevertheless recommends that companies submit protocols and study reports in the same manner for voluntary PASS, although this is not mandatory. citeturn0search0

Thus, similar scientific practice can coexist with different regulatory status.

7. The Study Design Does Not Determine Regulatory Status

A retrospective database study, prospective cohort study, registry study or systematic review can potentially be used as a PASS. The scientific design therefore does not tell the organisation whether the PASS is imposed.

The regulatory status must instead be established from the underlying authorisation, regulatory request, RMP and applicable legal documentation.

This distinction is important when study teams are designing protocols: epidemiologists address the scientific design, while pharmacovigilance and regulatory functions must also establish the legal and procedural context.

8. Who Owns the Classification?

The MAH should have a controlled process for determining and documenting the regulatory basis of its PASS activities.

Scientific teams may identify the study question and design, but classification can require input from pharmacovigilance and regulatory functions because the distinction may depend on the wording of an authorisation condition, specific obligation, regulatory request or agreed RMP.

The QPPV should have appropriate visibility of significant imposed obligations and their consequences for the pharmacovigilance system.

9. What Does Not Change?

Whether a PASS is imposed or voluntary, the organisation still needs an appropriate scientific question, a suitable design, reliable data, appropriate analysis and a credible interpretation of the results.

GVP Module VIII establishes standards for transparency, scientific and quality considerations for the relevant non-interventional PASS framework. citeturn0search21

The regulatory difference concerns the source and consequences of the obligation, not permission to lower scientific standards for a voluntary study.

10. Practical Classification Scenarios

A voluntary registry study can generate findings that materially affect the safety profile. Its voluntary origin does not make those findings optional; they must enter the normal pharmacovigilance assessment process.

Conversely, an RMP study should not be labelled imposed merely because it appears in the RMP. The regulatory basis must be checked against the applicable authorisation and regulatory documentation.

Finally, if a marketing authorisation contains a specific obligation to conduct a PASS, treating the project as an ordinary voluntary epidemiological study risks losing the regulatory milestones and procedural controls attached to the obligation.

Key Takeaways

The distinction between imposed and non-imposed PASS begins with the regulatory basis of the study, not its scientific design.

An imposed non-interventional PASS is subject to specific EU regulatory requirements. A voluntary PASS or an RMP-related PASS can be equally important scientifically without automatically acquiring the legal status of an imposed PASS.

The classification should therefore be established early, documented explicitly and revisited when the regulatory circumstances change.

References

1. European Medicines Agency. GVP Module VIII — Post-authorisation safety studies.
2. European Medicines Agency. Post-authorisation safety studies (PASS), including current procedural advice and Q&A.
3. European Medicines Agency. GVP Module VIII Addendum I — Requirements and recommendations for submission of information on non-interventional PASS.
4. Directive 2001/83/EC, as amended, including Articles 22a and 107m–107q.
5. Regulation (EC) No 726/2004, as amended.
6. Commission Implementing Regulation (EU) No 520/2012, as amended.

Regulatory Note

This article distinguishes regulatory categories for PASS for educational purposes. The applicable status of an individual study should be determined from its current regulatory documentation, authorisation conditions, RMP and applicable EU and national requirements.

EMA procedural guidance and GVP modules are periodically updated. Current requirements should be verified before applying this framework to an actual study.

Practical scenarios are illustrative unless an authoritative source is specifically identified.

11. The Regulatory Consequences of Imposition

The practical difference between imposed and non-imposed PASS becomes clearer once the study moves from classification into execution. An imposed study sits within a defined regulatory procedure; a non-imposed study is governed primarily through the MAH's pharmacovigilance system, applicable GVP expectations and any other requirements arising from its particular status.

For imposed non-interventional PASS, the legal framework establishes specific requirements for protocol submission, substantial amendments and final study reports. GVP Module VIII Addendum I states that the draft protocol and relevant amended protocol are submitted through the applicable procedure and that the final study report is subject to the imposed-PASS submission framework. citeturn0search23

The first operational consequence of classification is therefore procedural control.

12. Protocol Submission and Approval

An imposed PASS should not be treated as an ordinary internal research protocol. The protocol forms part of the regulatory record and must be managed according to the applicable procedure.

This affects how the organisation controls:

• protocol versions;
• regulatory submission;
• authority comments;
• protocol amendments;
• milestones;
• and evidence of endorsement or acceptance where applicable.

For voluntary PASS, EMA recommends use of the same submission approach, but the recommendation does not turn the voluntary study into an imposed study. citeturn0search0

The distinction between legal requirement and recommended operational standard should remain explicit in the quality system.

13. Protocol Amendments

A protocol change must be assessed according to both its scientific significance and the regulatory status of the study.

A change to the study question, population, design, data source, outcome definition or statistical analysis may alter the validity of the evidence. For an imposed PASS, a substantial amendment can also trigger a defined regulatory procedure.

The correct sequence is therefore:

Proposed change
      ↓
Scientific impact assessment
      ↓
Does it affect the study objectives/design or regulatory milestone?
      ↓
Determine whether the change is substantial
      ↓
Apply the procedure appropriate to the PASS status
      ↓
Implement and document

The study team should not implement a material change first and determine its regulatory significance afterwards.

14. The Regulatory Basis Determines the Change-Control Path

Two studies can make the same scientific change but require different regulatory handling because their regulatory status differs.

For example, an imposed PASS may require submission of a substantial amendment through the applicable authority procedure. A voluntary study may instead be controlled through the MAH's own quality and scientific governance process, subject to any other applicable requirements.

The scientific classification of the amendment and the regulatory classification of the study therefore need to be considered together.

15. Final Study Results

For imposed non-interventional PASS, the final study report enters a defined regulatory process. EMA explains that only study reports considered final by the MAH should be submitted as final reports, and that the analytical dataset must be sufficiently complete to perform the analyses leading to the primary study results. citeturn0search0

This creates an important distinction between:

• interim information;
• incomplete analyses;
• study progress information; and
• the final study report.

The organisation should not label a report "final" merely because the project team wants to close the project. Finality has scientific and, for an imposed PASS, regulatory significance.

16. The Twelve-Month Final-Report Requirement

For imposed non-interventional PASS within the Article 107p framework, GVP Module VIII Addendum I states that the final study report shall be submitted within 12 months after the end of data collection. citeturn0search23

This is a legal requirement and should therefore be distinguished from internal target dates used to manage drafting, QC and approval.

The organisation should maintain a controlled chain from the regulatory milestone to the internal production schedule so that an internal delay is recognised before it becomes a regulatory delay.

17. Interim Results Are Not Automatically Final Results

A study can produce important information before its formal endpoint.

For an imposed non-interventional PASS, EMA states that interim results and feasibility studies do not fall under Articles 107n–q in the same way as the final study report. Where interim information is requested, the appropriate submission procedure depends on the circumstances and product authorisation route. citeturn0search0

This distinction matters because the organisation should have two capabilities at once: it must preserve the formal definition of the final report, while also allowing potentially important emerging safety information to enter the pharmacovigilance system without waiting unnecessarily for study completion.

18. Regulatory Assessment of Imposed PASS

For imposed non-interventional PASS, PRAC assesses protocols and final study outcomes within its remit, subject to the applicable national exception for a study conducted only in one Member State under Article 22a. citeturn0search0

The assessment is separate from the MAH's scientific conclusion.

The MAH therefore needs to preserve the distinction between:

1. what the study found;
2. what the MAH concluded;
3. what the regulator assessed; and
4. what regulatory action followed.

This distinction becomes especially important when the regulatory assessment reaches a different conclusion from the MAH.

19. What Happens After the Final Results?

A final study report does not necessarily represent the end of the pharmacovigilance process.

The result may affect:

• the safety specification;
• signal management;
• the RMP;
• risk-minimisation measures;
• product information;
• PSUR assessment;
• regulatory commitments;
• or further evidence generation.

For imposed PASS, the regulatory outcome may itself create further obligations. EMA publishes outcomes of imposed non-interventional PASS and explains that, where an assessment leads to variation of marketing authorisations, the affected MAHs must take the applicable regulatory action. citeturn0search3

The result therefore has to be connected to the wider product lifecycle.

20. Voluntary PASS: Different Legal Status, Same Pharmacovigilance Responsibility

A voluntary PASS does not become scientifically unimportant because it lacks an imposed obligation.

If the MAH conducts a study to answer an important safety question, the resulting evidence must still be evaluated through the pharmacovigilance system.

EMA recommends that voluntary PASS follow the same submission approach as imposed studies, although this is not mandatory. citeturn0search0

The practical advantage of following a consistent process is that it improves transparency, reproducibility and inspection readiness without misrepresenting the legal status of the study.

21. Voluntary Does Not Mean Uncontrolled

A voluntary study should still have:

• a defined objective;
• a controlled protocol;
• appropriate scientific governance;
• data-quality controls;
• documented analysis;
• medical and pharmacovigilance review;
• version control;
• and a documented conclusion.

The precise controls should be proportionate to the study and its significance. The key point is that absence of an imposed legal procedure does not justify absence of quality management.

22. RMP PASS and Regulatory Follow-Up

Where a PASS is included in the RMP, its results should be considered in the context of the risk-management objective that led to the study.

For example, if the study was designed to evaluate the effectiveness of a risk-minimisation measure, simply reporting the study result is insufficient. The organisation must determine what the result means for the effectiveness of the measure and whether the RMP or other risk-management activity needs to change.

The regulatory status of the study and the scientific significance of its result are therefore separate questions.

23. Practical Scenario: Same Study, Different Status

Imagine two MAHs conduct almost identical registry studies examining the same safety concern.

For MAH A, the competent authority imposed the study as a condition of the marketing authorisation. For MAH B, the study was voluntarily initiated.

The scientific methods may be almost identical, but the regulatory handling differs. MAH A must comply with the applicable imposed-PASS procedures and milestones. MAH B does not acquire those legal obligations merely because its scientific design resembles MAH A's study.

Both MAHs, however, remain responsible for scientifically evaluating their findings and taking appropriate pharmacovigilance action.

24. Practical Scenario: A Substantial Amendment

An imposed PASS originally planned to use one national database. The investigators discover that the database cannot provide a key outcome measure and propose replacing it with another source.

The change may have major implications for the study's validity. The organisation should assess the scientific impact first and then determine the regulatory procedure applicable to the amendment.

The correct approach is not to choose the new database immediately and update the protocol retrospectively.

25. Practical Scenario: A Final Report Is Delayed

An imposed PASS reaches the end of data collection, but statistical programming is delayed.

The organisation should distinguish the end of data collection from completion of the final report. The regulatory deadline remains relevant even though internal analysis work is incomplete.

The issue should therefore be escalated through the appropriate governance and regulatory process rather than treated solely as a project-management problem.

26. Practical Scenario: A Voluntary Study Finds a New Signal

A voluntary PASS identifies an unexpected adverse outcome that was not anticipated when the study began.

The absence of an imposed obligation does not permit the MAH to defer assessment until the next routine reporting cycle if the evidence warrants earlier evaluation.

The finding should enter the appropriate signal-management and medical assessment processes, with consideration of the RMP, PSUR, product information and regulatory reporting as applicable.

Key Takeaways

The regulatory basis of a PASS determines the procedural framework, particularly for imposed non-interventional PASS.

For imposed studies, protocol amendments, final-report submission and regulatory assessment are controlled through specific EU procedures. For voluntary studies, those procedures are generally recommendations rather than automatically applicable legal obligations.

The distinction does not reduce the MAH's responsibility for the scientific quality or pharmacovigilance significance of a voluntary study.

References

1. European Medicines Agency. GVP Module VIII — Post-authorisation safety studies.
2. European Medicines Agency. GVP Module VIII Addendum I.
3. European Medicines Agency. Post-authorisation safety studies (PASS), including current procedural advice and Q&A.
4. European Medicines Agency. Outcomes of imposed non-interventional PASS.
5. Directive 2001/83/EC, as amended.
6. Commission Implementing Regulation (EU) No 520/2012, as amended.

Regulatory Note

The distinction between legal requirements and recommended practice is essential. This article uses "shall"-type requirements only where the underlying EU framework establishes an obligation and describes other operational controls as recommended practice.

Current EMA procedural guidance should be checked before applying these principles to an individual PASS.

27. Governance Across the PASS Lifecycle

Once the regulatory basis has been established, governance should preserve that classification throughout the study lifecycle.

A useful control model is:

Regulatory basis
      ↓
Study inventory
      ↓
Protocol and milestones
      ↓
Study conduct
      ↓
Changes and deviations
      ↓
Results
      ↓
Regulatory / PV assessment
      ↓
Implementation
      ↓
Closure and follow-up

The purpose of this structure is not administrative complexity. It is to prevent the regulatory status from becoming detached from the decisions made during study conduct.

28. Regulatory Documentation as the Source of Truth

The classification should be traceable to authoritative documentation.

Depending on the study, this may include:

• the marketing authorisation;
• a Commission decision;
• a competent-authority request;
• an RMP;
• an agreed regulatory procedure;
• or other applicable regulatory documentation.

An internal database field stating "imposed" is not, by itself, evidence that the study is imposed.

The organisation should be able to show why the classification was made and who reviewed it.

29. Study Transfers and Changes in Ownership

A transfer of a marketing authorisation or a change in the organisation managing the PASS should trigger review of the study's regulatory status and outstanding obligations.

The incoming organisation should understand:

• why the study exists;
• whether it is imposed;
• which regulatory document created the obligation;
• which milestones remain open;
• what has already been submitted;
• what authority interactions remain outstanding;
• and what actions are required after the final results.

The regulatory basis should therefore be transferred with the study rather than reconstructed later from project records.

30. Outsourcing Does Not Transfer Regulatory Responsibility

An MAH may use a CRO, database provider, epidemiology group or other external organisation to conduct a PASS.

The contractual arrangement does not change the regulatory basis of the study.

If an imposed PASS is outsourced, it remains an imposed PASS. If a voluntary PASS is outsourced, it does not become imposed because a third party is performing it.

The MAH should therefore maintain oversight of regulatory milestones, scientific interpretation, submissions and follow-up regardless of who performs the operational work.

31. Inspection Perspective: Can the Organisation Explain Why the Study Is Imposed?

An inspector may ask:

What is the regulatory basis for this PASS?

A strong answer does not rely on the study manager's recollection. It identifies the authoritative document, explains the classification and shows how the obligation was translated into operational controls.

The inspector may then ask what changed because the study was imposed.

The organisation should be able to demonstrate the applicable protocol, amendment, submission, milestone and regulatory-assessment controls.

32. Inspection Perspective: The Study Is in the RMP

An inspector finds that a PASS appears in the RMP but the internal study inventory labels it both "RMP PASS" and "imposed" without identifying an authorisation condition or competent-authority obligation.

The problem is not the terminology alone. The underlying concern is whether the organisation actually understands the regulatory basis and has therefore applied the correct procedural controls.

The corrective question is: What document establishes the obligation?

33. Inspection Perspective: Voluntary Study With Weak Governance

A voluntary PASS has no imposed submission deadline, so the organisation has allowed the protocol to change informally and has retained limited evidence of scientific review.

The absence of an imposed procedure does not justify weak scientific governance. The study still forms part of the MAH's pharmacovigilance system and should be controlled according to its significance and applicable GVP expectations.

The appropriate lesson is not that voluntary studies must always follow every imposed-PASS procedure. It is that their governance should be proportionate, deliberate and demonstrable.

34. Inspection Perspective: Regulatory Status Changed but the Inventory Did Not

A regulatory procedure changes the status or obligations associated with a study, but the study inventory is not updated.

The study team subsequently applies the old submission pathway and milestone schedule.

This illustrates why regulatory classification should not be a static field created when the study starts. It should be linked to regulatory intelligence and change control.

35. Inspection Perspective: Final Results Without Regulatory Closure

An imposed PASS final report has been completed, but the organisation has not identified whether the regulatory assessment requires changes to the marketing authorisation, RMP or risk-minimisation measures.

The final report is therefore being treated as the endpoint of the project rather than one stage in a regulatory lifecycle.

The organisation should preserve the connection between the final study result, the regulatory outcome and implementation.

36. A Practical Classification Record

A proportionate internal record might answer the following questions:

This record should support, rather than replace, the underlying regulatory documentation.

37. A Decision Tree for Operational Use

Is this a PASS?
      ↓ yes
Why is it being conducted?
      ↓
Was an obligation imposed by an EU competent authority?
      ├── Yes → imposed PASS framework
      │          ↓
      │     identify applicable legal/procedural route
      │
      └── No → non-imposed PASS
                 ↓
          Is it in the RMP or otherwise part of a defined PV activity?
                 ↓
          apply applicable GVP, RMP and quality-system controls

The decision tree is deliberately simple. The difficult part is usually not the logic but obtaining and interpreting the correct regulatory documentation.

38. When the Classification Is Unclear

If the available documents do not clearly establish the regulatory status, the organisation should not resolve the ambiguity by assuming the less burdensome category.

Regulatory and pharmacovigilance functions should review the source documents and determine the applicable interpretation. Where necessary, the organisation should seek appropriate regulatory clarification.

The classification should be resolved before a consequential deadline, submission or protocol change is allowed to pass.

39. Why This Distinction Matters to the QPPV

The QPPV's interest is not primarily in the label attached to the study. It is in whether the regulatory basis has been correctly translated into a functioning pharmacovigilance control.

For a significant imposed PASS, the QPPV should have assurance that the obligation is known, milestones are controlled, scientific results are assessed and regulatory consequences are implemented.

For a voluntary PASS, the QPPV should be able to establish that significant safety evidence generated by the study enters the appropriate pharmacovigilance processes even though the study is not subject to the imposed-PASS legal procedure.

The common governance principle is therefore effective control of safety evidence and its consequences.

40. Final Review Checklist

Before closing the classification and governance review for a PASS, confirm:

• the study's scientific purpose is documented;
• the PASS category is clear;
• the regulatory basis is identified;
• imposed status is supported by authoritative documentation where applicable;
• RMP inclusion is distinguished from regulatory imposition;
• applicable milestones are controlled;
• the submission pathway is known;
• protocol changes are assessed appropriately;
• final-report requirements are understood;
• regulatory outcomes are tracked where applicable;
• RMP, signal-management and product-information implications are assessed;
• outsourced activities remain under MAH oversight;
• and the QPPV has appropriate visibility of significant obligations and outcomes.

Key Takeaways

The imposed/non-imposed distinction is useful only when it changes how the study is governed.

For imposed PASS, the classification connects the study to specific legal procedures and regulatory milestones. For non-imposed PASS, the absence of those imposed procedures does not remove the need for scientific quality, pharmacovigilance assessment or appropriate governance.

The most reliable system keeps the regulatory basis, study inventory, protocol, submissions, results and follow-up connected. That makes the classification understandable to the study team, the QPPV, regulatory colleagues and an inspector.

References

1. European Medicines Agency. GVP Module VIII — Post-authorisation safety studies.
2. European Medicines Agency. GVP Module VIII Addendum I — Requirements and recommendations for submission of information on non-interventional PASS.
3. European Medicines Agency. Post-authorisation safety studies (PASS), including current procedural advice and Q&A.
4. European Medicines Agency. Outcomes of imposed non-interventional PASS.
5. European Medicines Agency. GVP Module V — Risk management systems.
6. Directive 2001/83/EC, as amended.
7. Regulation (EC) No 726/2004, as amended.
8. Commission Implementing Regulation (EU) No 520/2012, as amended.

Regulatory Note

This article is an educational explanation of the regulatory distinction between imposed and non-imposed PASS. The legal status of an individual study should always be determined from its current regulatory documentation and the applicable EU and national framework.

EMA guidance and procedures are periodically updated. Current requirements should be verified before making regulatory or operational decisions.

Inspection scenarios are illustrative unless an authoritative inspection source is specifically identified.